M

Mirum Pharmaceuticals

ASBT inhibitors for rare liver diseases

Executive Vice President - Head of International

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's, Master's, PhD
Foster City, CA, USA
HybridHybrid role; must be located in the San Francisco Bay Area or willing to relocate.
Business & Strategy

About the job

Requirements
  • A bachelor's degree is required; an advanced degree such as a master's or doctorate is preferred.
  • At least 15 years of progressive commercial leadership experience in the pharmaceutical or biotechnology industry, including substantial international responsibility.
  • Regional or country general management experience with profit-and-loss accountability.
  • Experience leading multi-country organizations through matrixed operating models.
  • Success launching and commercializing rare disease, specialty-care, or other high-value, low-prevalence products.
  • Experience with international pricing, reimbursement, market access, and launch sequencing.
  • Experience evaluating geographic expansion and building new regional, affiliate, or commercial capabilities.
  • Broad understanding of international biopharmaceutical commercialization, including regional and country operating models, direct and partner-led go-to-market approaches, pricing, reimbursement, distribution, and compliance.
  • Strategic, financial, and operational leadership, connecting portfolio choices to regional execution and measurable business outcomes.
  • Ability to build lean, fit-for-purpose organizations.
  • Ability to assess market attractiveness, access feasibility, launch requirements, and direct-versus-partner economics across diverse geographies.
  • Ability to influence senior leaders, program teams, and enterprise functions without relying solely on line authority.
  • Judgment, communication, negotiation, and relationship-building skills across cultures and organizational levels.
  • Ability to lead through ambiguity, organizational change, growth, and competing priorities.
  • Commitment to patient-centered decision-making, ethical leadership, and compliance.
  • Must be located in the San Francisco Bay Area or willing to relocate.
  • Experience in both a large global organization and a smaller or emerging biotechnology environment is preferred.
Responsibilities
  • Own the international business plan, profit-and-loss responsibility, resource allocation, forecast, operating priorities, and performance-management process for markets outside the United States.
  • Translate enterprise and portfolio strategy into executable regional plans for Europe and the Middle East, Canada, Latin America, and Asia Pacific.
  • Provide executive leadership with a clear view of international performance, opportunities, risks, and investment priorities.
  • Represent the senior international commercial perspective in enterprise portfolio, lifecycle, evidence, and business-development decisions.
  • Ensure disciplined execution of global price corridors.
  • Build a high-performing international leadership team and operating model.
  • Develop existing regional and country leaders while scaling direct and distributor markets into a multi-product business across Europe, Canada, and the Middle East.
  • Ensure launch readiness, market access, pricing and reimbursement, key opinion leader development, commercial execution, and partner performance across the region.
  • Build and lead a regional leadership team for Asia Pacific and Latin America, establish regional strategies, operating models, and performance expectations, and develop market-prioritization frameworks.
  • Recommend commercial models for priority markets, including partner-led, direct, and licensing approaches.
  • Lead ex-U.S. launch readiness across the portfolio, including access, pricing, evidence generation, supply readiness, and launch sequencing.
  • Ensure development and commercialization strategies incorporate international market requirements, and establish repeatable launch-excellence processes across products and geographies.
  • Assess business-development opportunities and potential products through an international commercial and access lens.
  • Drive post-launch performance and sharing of best practices across markets.
  • Establish performance expectations, decision rights, escalation processes, and key performance indicators for distributors and license partners.
  • Drive partner performance across registration, access, commercialization, and supply; build accountable partnerships that advance strategic and financial objectives.
  • Develop direct-versus-partner recommendations for priority markets and present investment cases to executive leadership.
  • Oversee international pricing architecture and price-corridor execution, including international reference-pricing considerations in launch sequencing and contracting decisions.
  • Align regional access strategies with global evidence priorities, product value narratives, and local reimbursement requirements.
  • Establish disciplined forecasting, analytics, and business-planning processes, and ensure international market needs inform product, lifecycle, and evidence-generation planning.
  • Lead, coach, and develop a geographically dispersed, multicultural leadership team with clear accountability for business outcomes.
  • Partner with U.S. Commercial, Medical Affairs, Clinical Development, Regulatory, Finance, Legal, Compliance, CMC, Supply Chain, Quality, Safety, Patient Advocacy, and program teams.
  • Influence enterprise decisions through strategic clarity, operational credibility, and cross-functional relationships.
  • Build scalable capabilities, processes, succession depth, and leadership capacity for a growing rare disease company.
  • Represent the company with external partners, government and reimbursement stakeholders, patient communities, and other senior external audiences, as appropriate.
Desired Qualifications
  • Experience in both a large global organization and a smaller or emerging biotechnology environment.

About the company

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ATEBRIOZ won FDA approval on September 25, 2026, creating a new commercial launch.
  • Second-quarter 2026 revenue reached $176.2 million, and management raised 2026 guidance to $680-$700 million.
  • Brelovitug hit its Phase 3 AZURE-1 endpoint on September 28, 2026, strengthening launch odds.

What critics are saying

  • FDA told Mirum to run another Phase 3 for volixibat, pushing PSC filing to H1 2027.
  • Brelovitug still needs AZURE-4 in Q4 2026 before a H1 2027 BLA submission.
  • A failure in LIVMARLI, brelovitug, or ATEBRIOZ would leave Mirum heavily concentrated.

What makes Mirum Pharmaceuticals unique

  • Mirum now has three late-stage programs: LIVMARLI, brelovitug, and ATEBRIOZ.
  • LIVMARLI keeps expanding across pediatric cholestatic diseases, reinforcing a rare-liver-disease franchise.
  • Brelovitug targets chronic hepatitis delta with no approved U.S. competitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

1%

1 year growth

3%

2 year growth

2%
WQXC
Sep 28th, 2026
Mirum's liver infection drug lowers virus levels in late-stage study.

Mirum's liver infection drug lowers virus levels in late-stage study. By Thomson Reuters Sep 28, 2026 | 8:49 AM By Sneha S K Sept 28 (Reuters) - Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study. Here are some key details: - Mirum was testing brelovitug, an experimental monoclonal antibody that binds to the hepatitis B surface antigen, a protein found on the surface of the virus - The company was testing the treatment for chronic hepatitis delta virus, a liver infection that affects people already infected with hepatitis B - The disease, which the company estimates affects about 230,000 people in the US and Europe, can cause severe symptoms that can lead to liver damage and, in some cases, death - At 24 weeks, 56% of patients given 300 milligrams of brelovitug and 45% of those given 900 milligrams showed reduced hepatitis D virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group, the company said - The company expects the drug to generate peak sales of at least $1 billion - The only FDA-approved treatment for the condition is Gilead's Hepcludex - "Brelovitug has a better benefit/risk profile," said RBC Capital Markets analyst Lisa Walter, adding that the latest results position it as the best-in-class treatment option - The drug was well tolerated across dose groups, with a safety profile consistent with previously reported data, Mirum said - Full results from the study will be presented at an upcoming medical congress, with the company expecting to submit a marketing application for the drug to the US FDA in the first half of 2027. (Reporting by Sneha S K in Bengaluru; Editing by Jonathan Ananda and Diti Pujara)

Business Wire
Sep 25th, 2026
FDA approves Atebrioz for rare bone disease fibrodysplasia ossificans progressiva

The US Food and Drug Administration has approved Atebrioz (zilurgisertib) for adult and paediatric patients aged 12 and older with fibrodysplasia ossificans progressiva, a rare genetic disease affecting approximately 300 people in the United States. Mirum Pharmaceuticals and Incyte announced the approval, which makes Atebrioz the latest treatment option for the progressive condition that causes bone to form in muscles, tendons, and other soft tissues. The once-daily oral tablet works by inhibiting ALK2, targeting the disease-driving pathway. Clinical trial data showed that at 24 weeks, mean total new heterotopic ossification volume decreased by 3.2 cm³ in patients receiving the drug compared with an increase of 24.6 cm³ in placebo-treated patients. Atebrioz is expected to be commercially available in October through Mirum Access Plus, with eligible patients paying as little as $0 per month.

IFOPA
Sep 25th, 2026
U.S. FDA approves Mirum Pharmaceuticals' zilurgisertib as a treatment for FOP.

U.S. FDA approves Mirum Pharmaceuticals' zilurgisertib as a treatment for FOP. Posted on September 25, 2026 Atebrioz(TM) is the third treatment approved for people living with FOP in the United States. Today, September 25, is an incredible day for the FOP community! IFOPA want to start by thanking FOP community members from around the world who participated in the zilurgisertib trial. Mirum Pharmaceuticals and Incyte have announced the U.S. Food & Drug Administration's (FDA) approval of zilurgisertib tablets for the treatment of fibrodysplasia ossificans progressiva (FOP) in the United States. Zilurgisertib is the first FOP drug approved after completing only a Phase 2 clinical trial. * The brand name of the drug is Atebrioz(TM) * Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP. * Mirum will soon release websites to help people with FOP and their local healthcare providers learn more about Atebrioz. * Atebrioz is expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month. * Atebrioz is only available for treatment of FOP for individuals in the United States. * The European Medicines Agency (EMA) in the European Union is also reviewing zilurgisertib. Letter from Mirum's CEO. Thank you. Zilurgisertib (now known as Atebrioz) was tested in the PROGRESS Phase 2 clinical trial. IFOPA is deeply grateful to the 63 people with FOP who participated. IFOPA is also grateful to the Principal Investigators, Study Coordinators, and all of the staff at the trial sites who took such good care of its families. IFOPA want to thank Novartis, Incyte, and Mirum for their commitment and dedication to the FOP community. Publications & Presentations. The links below include press releases, a poster, and a plain language summary of the PROGRESS trial results. IFOPA expect a publication in a peer-reviewed journal. Presentations from the 2026 7th FOP Drug Development Forum Incyte shared this poster and plain-language summary of their results, which show an 81% reduction in the proportion of patients with new lesions at Week 24 (compared to placebo), at ENDO 2026, the leading global meeting on endocrinology research and clinical care hosted by the Endocrine Society. Where is Atebrioz approved? It is important to note that the FDA's approval of Atebrioz is only for people aged 12 and older with FOP living in the United States. On August 5, 2026, Mirum announced during an Investor Call that the EMA in the European Union accepted zilurgisertib for review. IFOPA await the EMA's decision. In what other countries is Mirum seeking approval of zilurgisertib? Zilurgisertib previously received Fast Track designation and Orphan Drug Designation from the FDA, as well as Orphan Designation by the European Medicines Agency in the European Union. IFOPA communicate regularly with Mirum about developments with zilurgisertib and will share announcements with the FOP community when they are publicly available. Is zilurgisertib in a trial for children younger than 12? The PROGRESS Phase 2 trial includes an active Cohort 2 for children ages 6 to < 12 years of age that is fully enrolled. Cohort 3 for children ages 2 to < 12 years is recruiting. You can learn more at ifopa.org/progress If you would like to receive updates on clinical trials and drug reviews, please sign up for IFOPA's Clinical Trial Alerts at ifopa.org/clinical-trial-alerts About zilurgisertib. People with FOP harbor mutations in the ALK2 protein (also known as ACVR1) that drives excessive bone morphogenetic protein (BMP) signaling, which regulates cartilage and bone development. Zilurgisertib (INCB000928) is an oral investigational drug designed to target and block this disease-causing mutant FOP protein hyperactivity. In preclinical studies, zilurgisertib demonstrated potency for the target kinase, selectivity, safety and strong suppression of heterotopic ossification (HO) in animal models.

Yahoo Finance
Sep 8th, 2026
Mirum Pharmaceuticals appoints Dr Rob Myers as chief medical officer

Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.

CNBC TV18
Aug 20th, 2026
US FDA approves Regeneron's rare bone disorder drug.

US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.